Protease inhibitors could be highly effective against SARS-CoV-2
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
List view / Grid view
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
Researchers found there is a gradient of SARS-CoV-2 infectivity down the airway and that the severe pneumonia symptoms may be caused by aspiration of oral contents into the lungs.
Collaboration between scientists, illustrators and simulators has culminated in highly detailed three-dimensional (3D) models of SARS-CoV-2.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Macaques were protected against SARS-CoV-2 infection both after an initial infection and vaccination with a prototype vaccine, researchers suggest humans could respond similarly.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
A group of researchers has found that SARS-CoV-2 may not spread by faecal-to-oral transmission, but is able to infect the gastrointestinal tract via the TMPRSS2 and TMPRSS4 enzymes.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.